Please use this identifier to cite or link to this item:
Title: A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance.
Austin Authors: Manning, Brooke;Arkell, Thomas R;Hayley, Amie C ;Downey, Luke A
Affiliation: Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.
Institute for Breathing and Sleep
Issue Date: Mar-2024
Date: 2024
Publication information: Journal of Psychopharmacology (Oxford, England) 2024-03; 38(3)
Abstract: Despite increasing medical cannabis use, research has yet to establish whether and to what extent products containing delta-9-tetrahydrocannabinol (THC) impact driving performance among patients. Stable doses of prescribed cannabinoid products during long-term treatment may alleviate clinical symptoms affecting cognitive and psychomotor performance. To examine the effects of open-label prescribed medical cannabis use on simulated driving performance among patients. In a semi-naturalistic laboratory study, 40 adults (55% male) aged between 23 and 80 years, consumed their own prescribed medical cannabis product. Driving performance outcomes including standard deviation of lateral position (SDLP), the standard deviation of speed (SDS), mean speed and steering variability were evaluated using the Forum8 driving simulator at baseline (pre-dosing), 2.5 h and 5 -h (post-dosing). Perceived driving effort (PDE) was self-reported after each drive. Oral fluid and whole blood samples were collected at multiple timepoints and analysed for THC via liquid chromatography-mass spectrometry. A significant main effect of time was observed for mean speed (p = 0.014) and PDE (p = 0.020), with patients displaying modest stabilisation of vehicle control, increased adherence to speed limits and reductions in PDE post-dosing, relative to baseline. SDLP (p = 0.015) and PDE (p = 0.043) were elevated for those who consumed oil relative to flower-based products. Detectable THC concentrations were observed in oral fluid at 6-h post-dosing (range = 0-24 ng/mL). This semi-naturalistic study suggests that the consumption of medical cannabis containing THC (1.13-39.18 mg/dose) has a negligible impact on driving performance when used as prescribed.
DOI: 10.1177/02698811241229524
ORCID: 0000-0001-5233-8191
Journal: Journal of Psychopharmacology (Oxford, England)
Start page: 2698811241229524
PubMed URL: 38332655
ISSN: 1461-7285
Type: Journal Article
Subjects: Driving performance
medical cannabis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.